Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 13 de 13
Filter
1.
J Immunol ; 188(1): 445-53, 2012 Jan 01.
Article in English | MEDLINE | ID: mdl-22116830

ABSTRACT

Microglia are activated by pathogen-associated molecular patterns and produce proinflammatory cytokines, such as TNF-α, IL-6, and IL-12, and the anti-inflammatory cytokine IL-10. Adenosine is an endogenous purine nucleoside and a ligand of four G protein-coupled adenosine receptors (ARs), which are the A(1)AR, A(2A)AR, A(2B)AR, and A(3)AR. ARs have been shown to suppress TNF-α production by microglia, but their role in regulating IL-10 production has not been studied. In this study, we demonstrate that adenosine augments IL-10 production by activated murine microglia while suppressing the production of proinflammatory cytokines. Because the order of potency of selective AR agonists in inducing IL-10 production was NECA > IB-MECA > CCPA ≥ CGS21680, and the A(2B)AR antagonist MRS1754 prevented the effect of NECA, we conclude that the stimulatory effect of adenosine on IL-10 production is mediated by the A(2B)AR. Mechanistically, adenosine augmented IL-10 mRNA accumulation by a transcriptional process. Using mutant IL-10 promoter constructs we showed that a CREB-binding region in the promoter mediated the augmenting effect of adenosine on IL-10 transcription. Chromatin immunoprecipitation analysis demonstrated that adenosine induced CREB phosphorylation at the IL-10 promoter. Silencing CREB using lentivirally delivered short hairpin RNA blocked the enhancing effect of adenosine on IL-10 production, confirming a role for CREB in mediating the stimulatory effect of adenosine on IL-10 production. In addition, adenosine augmented IL-10 production by stimulating p38 MAPK. Collectively, our results establish that A(2B)ARs augment IL-10 production by activated murine microglia.


Subject(s)
Adenosine/immunology , Interleukin-10/immunology , MAP Kinase Signaling System/immunology , Microglia/immunology , Nerve Tissue Proteins/immunology , Receptor, Adenosine A2B/immunology , Acetamides/pharmacology , Adenosine/pharmacology , Adenosine A2 Receptor Agonists/immunology , Adenosine A2 Receptor Agonists/pharmacology , Adenosine A2 Receptor Antagonists/pharmacology , Analgesics/immunology , Analgesics/pharmacology , Animals , CREB-Binding Protein/immunology , CREB-Binding Protein/metabolism , Cell Line , Interleukin-10/biosynthesis , MAP Kinase Signaling System/drug effects , Mice , Microglia/cytology , Microglia/metabolism , Nerve Tissue Proteins/agonists , Nerve Tissue Proteins/antagonists & inhibitors , Nerve Tissue Proteins/metabolism , Phosphorylation/drug effects , Phosphorylation/immunology , Promoter Regions, Genetic/immunology , Purines/pharmacology , RNA, Messenger/biosynthesis , RNA, Messenger/immunology , Receptor, Adenosine A2B/metabolism , Transcription, Genetic/drug effects , Transcription, Genetic/immunology , p38 Mitogen-Activated Protein Kinases/immunology , p38 Mitogen-Activated Protein Kinases/metabolism
2.
FASEB J ; 26(1): 376-86, 2012 Jan.
Article in English | MEDLINE | ID: mdl-21926236

ABSTRACT

Adenosine has been implicated in suppressing the proinflammatory responses of classically activated macrophages induced by Th1 cytokines. Alternative macrophage activation is induced by the Th2 cytokines interleukin (IL)-4 and IL-13; however, the role of adenosine in governing alternative macrophage activation is unknown. We show here that adenosine treatment of IL-4- or IL-13-activated macrophages augments the expression of alternative macrophage markers arginase-1, tissue inhibitor of matrix metalloproteinase-1 (TIMP-1), and macrophage galactose-type C-type lectin-1. The stimulatory effect of adenosine required primarily A(2B) receptors because the nonselective adenosine receptor agonist 5'-N-ethylcarboxamidoadenosine (NECA) increased both arginase activity (EC(50)=261.8 nM) and TIMP-1 production (EC(50)=80.67 nM), and both pharmacologic and genetic blockade of A(2B) receptors prevented the effect of NECA. A(2A) receptors also contributed to the adenosine augmentation of IL-4-induced TIMP-1 release, as both adenosine and NECA were less efficacious in augmenting TIMP-1 release by A(2A) receptor-deficient than control macrophages. Of the transcription factors known to drive alternative macrophage activation, CCAAT-enhancer-binding protein ß was required, while cAMP response element-binding protein and signal transducer and activator of transcription 6 were dispensable in mediating the effect of adenosine. We propose that adenosine receptor activation suppresses inflammation and promotes tissue restitution, in part, by promoting alternative macrophage activation.


Subject(s)
Adenosine/metabolism , Inflammation/metabolism , Macrophages/immunology , Macrophages/metabolism , Receptor, Adenosine A2A/metabolism , Receptor, Adenosine A2B/metabolism , Adenosine/pharmacology , Adenosine-5'-(N-ethylcarboxamide)/pharmacology , Animals , Arginase/metabolism , CCAAT-Enhancer-Binding Protein-beta/metabolism , Cell Line , Cyclic AMP Response Element-Binding Protein/metabolism , Extracellular Space/metabolism , Inflammation/immunology , Interleukin-13/metabolism , Interleukin-4/metabolism , Macrophages/drug effects , Male , Mice , Mice, Inbred C57BL , Mice, Knockout , Receptor, Adenosine A2A/genetics , Receptor, Adenosine A2A/immunology , Receptor, Adenosine A2B/genetics , Receptor, Adenosine A2B/immunology , STAT6 Transcription Factor/metabolism , Tissue Inhibitor of Metalloproteinase-1/metabolism , Toll-Like Receptor 4/immunology , Toll-Like Receptor 4/metabolism , Vasodilator Agents/pharmacology
3.
J Immunol ; 185(1): 542-50, 2010 Jul 01.
Article in English | MEDLINE | ID: mdl-20505145

ABSTRACT

Despite intensive research, efforts to reduce the mortality of septic patients have failed. Adenosine is a potent extracellular signaling molecule, and its levels are elevated in sepsis. Adenosine signals through G-protein-coupled receptors and can regulate the host's response to sepsis. In this study, we studied the role of A(2B) adenosine receptors in regulating the mortality and inflammatory response of mice following polymicrobial sepsis. Genetic deficiency of A(2B) receptors increased the mortality of mice suffering from cecal ligation and puncture-induced sepsis. The increased mortality of A(2B) knockout mice was associated with increased levels of inflammatory cytokines and chemokines and augmented NF-kappaB and p38 activation in the spleen, heart, and plasma in comparison with wild-type animals. In addition, A(2B) receptor knockout mice showed increased splenic apoptosis and phosphatase and tensin homolog activation and decreased Akt activation. Experiments using bone-marrow chimeras revealed that it is the lack of A(2B) receptors on nonhematopoietic cells that is primarily responsible for the increased inflammation of septic A(2B) receptor-deficient mice. These results indicate that A(2B) receptor activation may offer a new therapeutic approach for the management of sepsis.


Subject(s)
Inflammation Mediators/physiology , Receptor, Adenosine A2B/physiology , Sepsis/mortality , Sepsis/prevention & control , Acute Lung Injury/microbiology , Acute Lung Injury/mortality , Acute Lung Injury/prevention & control , Adenosine A2 Receptor Antagonists , Animals , Cecum , Inflammation Mediators/antagonists & inhibitors , Inflammation Mediators/metabolism , Ligation , Male , Mice , Mice, Inbred C57BL , Mice, Knockout , Peritonitis/microbiology , Peritonitis/mortality , Peritonitis/prevention & control , Punctures/adverse effects , Receptor, Adenosine A2B/deficiency , Sepsis/microbiology , Survival Rate
4.
FASEB J ; 24(8): 2631-40, 2010 Aug.
Article in English | MEDLINE | ID: mdl-20371613

ABSTRACT

Activation-induced cell death (AICD) is initiated by T-cell receptor (TCR) restimulation of already activated and expanded peripheral T cells and is mediated through Fas/Fas ligand (FasL) interactions. Adenosine is a purine nucleoside signaling molecule, and its immunomodulatory effects are mediated by 4 G-protein-coupled receptors: A(1), A(2A), A(2B), and A(3). In this study, we investigated the role of A(2A) receptors in regulating CD4(+) T lymphocyte AICD. Our results showed that the selective A(2A) receptor agonist CGS21680 (EC(50)=15.2-32.6 nM) rescued mouse CD4(+) hybridomas and human Jurkat cells from AICD and that this effect was reversed by the selective A(2A) receptor antagonist ZM241385 (EC(50)=2.3 nM). CGS21680 decreased phosphatidylserine exposure on the membrane, as well as the cleavage of caspase-3, caspase-8 and poly(ADP-ribose) polymerase indicating that A(2A) receptor stimulation blocks the extrinsic apoptotic pathway. In addition, CGS21680 attenuated both Fas and FasL mRNA expression. This decrease in FasL expression was associated with decreased activation of the transcription factor systems NF-kappaB, NF-ATp, early growth response (Egr)-1, and Egr-3. The antiapoptotic effect of A(2A) receptor stimulation was mediated by protein kinase A. Together, these results demonstrate that A(2A) receptor activation suppresses the AICD of peripheral T cells.


Subject(s)
Apoptosis , CD4-Positive T-Lymphocytes/cytology , Lymphocyte Activation , Receptor, Adenosine A2A/metabolism , Animals , Apoptosis/immunology , CD4-Positive T-Lymphocytes/immunology , Cell Death , Fas Ligand Protein/genetics , Humans , Jurkat Cells , Mice , Protective Agents , fas Receptor/genetics
5.
FASEB J ; 22(10): 3491-9, 2008 Oct.
Article in English | MEDLINE | ID: mdl-18625677

ABSTRACT

Adenosine is an immunosuppressive nucleoside, and adenosine A(2A) receptors inhibit T-cell activation. We investigated the role of A(2A) receptors in regulating T helper (Th)1- and Th2-cell development and effector function. A(2A)-receptor stimulation suppressed the development of T-cell receptor (TCR) -stimulated naive T cells into both Th1 and Th2 cells, as indicated by decreased IFN-gamma production by cells developed under Th1-skewing conditions and decreased interleukin (IL) -4, IL-5, and IL-10 production by cells developed under Th2-skewing conditions. Using A(2A) receptor-deficient mice, we demonstrate that A(2A) receptor activation inhibits Th1- and Th2-cell development by decreasing the proliferation and IL-2 production of naive T cells, irrespective of whether the cells are expanded under Th1- or Th2-skewing environment. Using in vivo established Th1 and Th2 cells, we further demonstrate the nonselective nature of A(2A) receptor-mediated immunosuppressive effects, because A(2A) receptor activation decreased IFN-gamma and IL-4 secretion and mRNA level of TCR-stimulated effector Th1 and Th2 cells, respectively. A(2A) receptor mRNA expression in both Th1 and Th2 effector cells increased following TCR stimulation. In summary, these data demonstrate that A(2A) receptor activation has strong inhibitory actions during early developmental, as well as late effector, stages of Th1- and Th2-cell responses.


Subject(s)
Adenosine A2 Receptor Agonists , Lymphocyte Activation , Th1 Cells/immunology , Th2 Cells/immunology , Animals , CD3 Complex/immunology , CD4 Antigens/immunology , Cell Line , Female , Interferon-gamma/biosynthesis , Interleukin-4/biosynthesis , Lymphocyte Activation/genetics , Male , Mice , Mice, Knockout , RNA, Messenger/biosynthesis , Receptor, Adenosine A2A/genetics , Receptor, Adenosine A2A/physiology
6.
Neurochem Int ; 52(1-2): 52-9, 2008 Jan.
Article in English | MEDLINE | ID: mdl-17640770

ABSTRACT

The discovery of nonsynaptic communication in the 1960s and 1970s was an important milestone in investigating the function of the nervous system, and it revolutionized our view about information transmission between neurons. In addition, nonsynaptic communication has a practical importance not only within the nervous system, but in the communication between the peripheral nervous system and other organ systems. Nonsynaptic communication takes place in different immune organs, which are innervated by sympathetic nerve terminals. In addition, the function of microglia, one of the immunocompetent cell types of the brain, can also be affected by neurotransmitters released from axon varicosities. The various functions of immune cells are modulated by released neurotransmitters without any direct synaptic contact between nerve endings and targeted immune cells requiring only functional neurotransmitter receptors on immune cells. Here, we briefly overview the role of the various receptor subtypes mediating nonsynaptic modulation of the function of immunocompetent cells both in the periphery and in the central nervous system.


Subject(s)
Cell Communication , Animals , Humans , Immune System , Receptors, Adrenergic/physiology , Receptors, Purinergic P1/physiology , Synapses/physiology
7.
Immunology ; 122(4): 503-13, 2007 Dec.
Article in English | MEDLINE | ID: mdl-17949419

ABSTRACT

Adrenergic signalling of the immune system is one of the important modulator pathways of the inflammatory immune response realized via G protein-mediated pathways. The resulted signal depends on the type of the receptor-coupled G-protein (GPCR) that, according to the classical paradigm in the case of beta-adrenergic receptor (beta-AR), is Gs-type. Recently, alternate and/or multiple G protein coupling specificity of GPCRs have been demonstrated including a switch from Gs to Gi binding. The possibility of a Gs/Gi switch and its role in the immune response of macrophages has not been investigated yet. In this study, we demonstrate that beta-adrenergic stimulation itself is able to induce a transient mitogen-activated protein kinase phosphorylation in murine peritoneal macrophages in a pertussis toxin-sensitive manner, suggesting that the Gs/Gi switch also occurs in the immune system. Although this process is very rapid, it can influence different signalling pathways and can reprogramme effector functions suggesting that sympathetic modulation of the defence mechanism of the innate immune system has an additional, Gs/Gi switch-dependent component.


Subject(s)
GTP-Binding Proteins/metabolism , Macrophages, Peritoneal/metabolism , Receptors, Adrenergic, beta/metabolism , Adrenergic beta-Agonists/pharmacology , Animals , Enzyme Activation/drug effects , Extracellular Signal-Regulated MAP Kinases/metabolism , GTP-Binding Protein alpha Subunits, Gi-Go/metabolism , GTP-Binding Protein alpha Subunits, Gs/metabolism , Isoproterenol/pharmacology , Lipopolysaccharides/immunology , Macrophages, Peritoneal/immunology , Mice , Mice, Inbred BALB C , Pertussis Toxin/immunology , Phosphorylation/drug effects , Signal Transduction/immunology , Tetradecanoylphorbol Acetate/immunology , Tumor Necrosis Factor-alpha/biosynthesis , p38 Mitogen-Activated Protein Kinases/metabolism
8.
Neurochem Int ; 49(1): 94-103, 2006 Jul.
Article in English | MEDLINE | ID: mdl-16515823

ABSTRACT

This is the first study to demonstrate that the interaction between beta-adrenoceptor activation, and the production of inflammatory mediators can be modulated in opposite ways by two inflammatory stimuli, namely, protein kinase C (PKC)-activating phorbol myristyl acetate (PMA) and lipopolysaccharide (LPS). We provided evidence that isoproterenol treatment, when combined with phorbol ester increased the production of tumor necrosis factor-alpha, interleukin-12, and nitric oxide in murine macrophages, as well as in human monocytes and differentiated PLB-985 cells, while in agreement with earlier findings, it decreased inflammatory mediator production in combination with LPS stimulation. The contrasting effect on inflammatory mediator production, shown for the PMA and LPS activated cells was accompanied by parallel changes in activation of ERK1/2 and p38 MAPKs. Thus, isoproterenol significantly increased MAPK activation (phosphorylation) in PMA-treated cells and, conversely, it decreased the activation of extracellular signal regulated kinase 1/2 (ERK1/2) and p38 in LPS-stimulated cells. The opposing effects of isoproterenol on LPS-induced versus PMA-induced mediator production and the concurrent changes in MAPK activation highlight the role of this kinase pathway in macrophage activation and provide new insights regarding the flexible ways through which beta-adrenoceptor stimulation can modulate the inflammatory response in macrophages. Our results challenge the dogma that beta-adrenoceptor signaling is only immunosuppressive, and offer potential opportunities for new therapeutic approaches in the treatment of inflammatory and autoimmune diseases.


Subject(s)
Inflammation Mediators/immunology , MAP Kinase Signaling System/immunology , Macrophages/immunology , Neuroimmunomodulation/immunology , Receptors, Adrenergic, beta/immunology , Adrenergic beta-Agonists/pharmacology , Animals , Carcinogens/pharmacology , Cell Line , Cells, Cultured , Enzyme Activation/drug effects , Enzyme Activation/immunology , Extracellular Signal-Regulated MAP Kinases/drug effects , Extracellular Signal-Regulated MAP Kinases/immunology , Extracellular Signal-Regulated MAP Kinases/metabolism , Humans , Inflammation Mediators/metabolism , Interleukin-12/immunology , Interleukin-12/metabolism , Isoproterenol/pharmacology , Lipopolysaccharides/pharmacology , MAP Kinase Signaling System/drug effects , Macrophages/drug effects , Macrophages/metabolism , Mice , Mice, Inbred BALB C , Neuroimmunomodulation/drug effects , Nitric Oxide/metabolism , Phosphorylation/drug effects , Receptors, Adrenergic, beta/drug effects , Receptors, Adrenergic, beta/metabolism , Tetradecanoylphorbol Acetate/pharmacology , Tumor Necrosis Factor-alpha/immunology , Tumor Necrosis Factor-alpha/metabolism , Up-Regulation/drug effects , Up-Regulation/immunology , p38 Mitogen-Activated Protein Kinases/drug effects , p38 Mitogen-Activated Protein Kinases/immunology , p38 Mitogen-Activated Protein Kinases/metabolism
9.
Curr Opin Pharmacol ; 2(4): 428-32, 2002 Aug.
Article in English | MEDLINE | ID: mdl-12127876

ABSTRACT

Basic and clinical studies have provided evidence that the biophase level of monoamines, determined by the balance of their release and uptake, is involved in the pathophysiology and treatment of depression, whereas other arguments cite the role of inflammatory mediators in the etiology of psychiatric disorders. A bidirectional interaction between the monoamine system and the inflammatory system might explain the concurrent therapeutical efficacy and immunomodulatory features of antidepressants.


Subject(s)
Adjuvants, Immunologic/therapeutic use , Antidepressive Agents/therapeutic use , Animals , Biogenic Monoamines/metabolism , Depression/immunology , Depression/metabolism , Depression/therapy , Humans
10.
Eur J Pharmacol ; 469(1-3): 175-81, 2003 May 23.
Article in English | MEDLINE | ID: mdl-12782200

ABSTRACT

Earlier studies demonstrated that cytokine production is under the tonic control of noradrenaline. As the level and/or the duration of noradrenaline action is regulated by the noradrenaline transporter (NET), which is also a target of antidepressant treatment, we studied its role in the regulation of the cytokine response during inflammation. The endotoxin-evoked tumour necrosis factor-alpha (TNF-alpha) and interleukin-10 response was studied in genetically produced noradrenaline transporter-deficient (NET-KO) mice and by treatment with desipramine, a monoamine uptake-blocker antidepressant. NET-KO mice responded to endotoxin with significantly lower TNF-alpha and interleukin-10 production in comparison to their wild-type counterparts. Functional involvement of both alpha- and beta-adrenoceptors could be demonstrated in our model systems, using 7,8-methylenedioxy-14 alpha-hydroxy-alloberbane.HCl (CH-38083) and propranolol; however, the differences between the two phenotypes remained, suggesting a limited role of alpha-adrenoceptors in the observed changes. Acute treatment of both wild-type and NET-KO mice with desipramine significantly decreased the TNF-alpha response and significantly increased interleukin-10 production, indicating the role of an intact noradrenaline transporter in anti-inflammatory responses.


Subject(s)
Adrenergic Fibers/metabolism , Berberine/analogs & derivatives , Cytokines/metabolism , Symporters/deficiency , Adrenergic Fibers/drug effects , Animals , Berberine/pharmacology , Interleukin-10/metabolism , Mice , Mice, Knockout , Norepinephrine Plasma Membrane Transport Proteins , Propranolol/pharmacology , Symporters/antagonists & inhibitors , Symporters/genetics , Tumor Necrosis Factor-alpha/metabolism
11.
Eur J Obstet Gynecol Reprod Biol ; 114(2): 236-8, 2004 Jun 15.
Article in English | MEDLINE | ID: mdl-15140522

ABSTRACT

OBJECTIVE: To study plasma TNF-alpha levels during normal pregnancy and the ex vivo endotoxin-induced TNF-alpha production of peripheral blood cells. STUDY DESIGN: In a longitudinal prospective study the ex vivo endotoxin-induced TNF-alpha production of peripheral blood cells and the plasma level of TNF-alpha in 18 women with uncomplicated pregnancies were determined at the 8th, 17th, 27th and 36th weeks of their pregnancy and 48 h and 6 weeks post-delivery. TNF-alpha levels were determined by ELISA technique. Data were analysed by Student's unpaired t-test. RESULTS: From the second trimester LPS-induced TNF-alpha production increased significantly (P<0.05) compared to non-pregnant values. In contrast, spontaneous TNF-alpha levels decreased with gestational age. Lowest values of plasma TNF-alpha levels and highest values of ex vivo endotoxin-induced TNF-alpha levels were detected at the 27th and 36th gestational weeks, respectively. Both parameters returned to non-pregnant levels after 6 weeks of delivery. CONCLUSION: Gestational age influences TNF-alpha production during normal pregnancy. The observed elevation of inducible TNF-alpha production may contribute to the immune defence of the mother against infections.


Subject(s)
Lipopolysaccharides/pharmacology , Tumor Necrosis Factor-alpha/analysis , Tumor Necrosis Factor-alpha/biosynthesis , Female , Gestational Age , Humans , Longitudinal Studies , Postpartum Period , Pregnancy , Prospective Studies
12.
Purinergic Signal ; 3(4): 447-52, 2007 Sep.
Article in English | MEDLINE | ID: mdl-18404457

ABSTRACT

Adenosine is a biologically active molecule that is formed at sites of metabolic stress associated with trauma and inflammation, and its systemic level reaches high concentrations in sepsis. We have recently shown that inactivation of A(2A) adenosine receptors decreases bacterial burden as well as IL-10, IL-6, and MIP-2 production in mice that were made septic by cecal ligation and puncture (CLP). Macrophages are important in both elimination of pathogens and cytokine production in sepsis. Therefore, in the present study, we questioned whether macrophages are responsible for the decreased bacterial load and cytokine production in A(2A) receptor-inactivated septic mice. We showed that A(2A) KO and WT peritoneal macrophages obtained from septic animals were equally effective in phagocytosing opsonized E. coli. IL-10 production induced by opsonized E. coli was decreased in macrophages obtained from septic A(2A) KO mice as compared to WT counterparts. In contrast, the release of IL-6 and MIP-2 induced by opsonized E. coli was higher in septic A(2A) KO macrophages than WT macrophages. These results suggest that peritoneal macrophages are not responsible for the decreased bacterial load and diminished MIP-2 and IL-6 production that are observed in septic A(2A) KO mice. In contrast, peritoneal macrophages may contribute to the suppressive effect of A(2A) receptor inactivation on IL-10 production during sepsis.

13.
Immunol Cell Biol ; 81(6): 472-9, 2003 Dec.
Article in English | MEDLINE | ID: mdl-14636244

ABSTRACT

Chronic granulomatous disease is an inherited disorder associated with a defect in phagocytic cell oxidative metabolism resulting in ineffective microbicidal activity. Consequently, patients with chronic granulomatous disease suffer from recurrent infections. Published data show that besides the failure to produce superoxide and its derivatives, other functional problems can also be found in chronic granulomatous disease-mutant cells. Since in innate immune responses other mediators, such as cytokines, also play an important role, we hypothesized that there may be a disturbance in cytokine production by chronic granulomatous disease-mutant cells as well. To prove this hypothesis, the production of tumour necrosis factor-alpha, an important proinflammatory cytokine, was determined by enzyme-linked immunosorbent assay in wild-type and chronic granulomatous disease-mutant myelomonoblastic PLB-985 cells in their immature, granulocytic and monocytic/macrophage differentiated forms. Tumour necrosis factor-alpha production was induced with N-formyl-L-methionyl-L-leucyl-L-phenylalanine (100 nmol/L), lipopolysaccharide (10 micro g/mL), opsonized zymosan (100 micro g/mL) or phorbol 12-myristate 13-acetate (100 nmol/L) for 24 h. We could demonstrate that: (i) there were marked differences in tumour necrosis factor-alpha production only in the differentiated forms of both wild-type and chronic granulomatous disease-mutant cells, while there were no differences in the case of their immature counterparts; (ii) only chronic granulomatous disease-mutant cells retained sensitivity to phorbol 12-myristate 13-acetate both in their granulocytic and monocytic forms, although phorbol 12-myristate 13-acetate responsiveness was a characteristic of both types of immature cells; (iii) the granulocytic form of wild-type cells produced tumour necrosis factor-alpha after opsonized zymosan stimulation, but such a response was not observed in cells originating from the chronic granulomatous disease-mutant cell line; (iv) with the monocytic forms, significantly higher tumour necrosis factor-alpha production could be induced by lipopolysaccharide in the wild-type cells than in the chronic granulomatous disease-mutant cells, although there was no difference in their lipopolysaccharide receptor CD14 expression. In summary, these data show an altered inducibility of tumour necrosis factor-alpha production by chronic granulomatous disease-mutant cells. Our observations suggest a further defect in differentiated chronic granulomatous disease-mutant cells in addition to the known defect in reduced nicotinamide adenine dinucleotide phosphate oxidase, which may contribute to the development of susceptibility to infections in people with chronic granulomatous disease.


Subject(s)
Granulocytes/immunology , Granulomatous Disease, Chronic/immunology , Monocytes/immunology , Receptors, Cell Surface/metabolism , Tumor Necrosis Factor-alpha/metabolism , Cell Differentiation/immunology , Cell Line, Tumor , Cells, Cultured , Granulocytes/drug effects , Granulomatous Disease, Chronic/genetics , Humans , Lipopolysaccharide Receptors/metabolism , Lipopolysaccharides/pharmacology , Macrophages/immunology , Monocytes/drug effects , Mutation , N-Formylmethionine Leucyl-Phenylalanine/pharmacology , Receptors, Cell Surface/immunology , Receptors, Complement 3b/metabolism , Receptors, IgG/metabolism , Tetradecanoylphorbol Acetate/pharmacology , Zymosan/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL